南予医学雑誌　第16巻

50/118

南予医誌　Vol.16　No. １　2015－48－Abstract　Advances in molecularly targeted therapy and other biologic agents have improved the effects of immunosuppressive therapy and chemotherapy. However, reactivation of hepatitis B virus (HBV) or the so-called “de novo HBV infection,” is becoming an important problem in patients who undergo these therapies. Guidelines for preventing immunosuppressive therapy- or chemotherapy-induced reactivation of HBV infection were announced by the Ministry of Health, Labor, and Welfare in Japan in 2009 but many medical professional are unaware of them. We set up inspection items for HBV infection and developed a reporting system to periodically provide the number of HBV-positive cases and follow the guidelines. The HBV-positive rate in our hospital was 35% (98/277), and the rate of occult HBV infec-tion (negative HB antigen) was 29%. This approach will help us understand this problem and follow the guidelines.（Nan-yo Med J 2015; 16: 43-48.）Immunosuppressive therapy or chemotherapy-induced hepatitis B virus reactivationYukie NISHIMOTO1),Tokihiro OHSHITA1),Kinpei AKAMATSU1)Yu HASHIMOTO2),Kenzo OKADA3)1) Department of Clinical Laboratory2) Department of Gastroenterology3) Department of SurgeryUwajima City HospitalGoten-machi,Uwajima,Ehime 798-8510,JAPAN